HRP20090151T3 - Indozolone derivatives as 11b-hsd1 inhibitors - Google Patents

Indozolone derivatives as 11b-hsd1 inhibitors

Info

Publication number
HRP20090151T3
HRP20090151T3 HR20090151T HRP20090151T HRP20090151T3 HR P20090151 T3 HRP20090151 T3 HR P20090151T3 HR 20090151 T HR20090151 T HR 20090151T HR P20090151 T HRP20090151 T HR P20090151T HR P20090151 T3 HRP20090151 T3 HR P20090151T3
Authority
HR
Croatia
Prior art keywords
alkyl
fluoro
alkoxy
hydrogen
aryl
Prior art date
Application number
HR20090151T
Other languages
English (en)
Croatian (hr)
Inventor
Amrein Kurt
Cai Jianping
Alan Jr. Goodnow Robert
Hunziker Daniel
Kuhn Bernd
Mayweg Alexander
Neidhart Werner
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20090151T3 publication Critical patent/HRP20090151T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20090151T 2004-09-29 2005-09-21 Indozolone derivatives as 11b-hsd1 inhibitors HRP20090151T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104753 2004-09-29
PCT/EP2005/010175 WO2006034804A1 (en) 2004-09-29 2005-09-21 Indozolone derivatives as 11b-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
HRP20090151T3 true HRP20090151T3 (en) 2009-04-30

Family

ID=35447579

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090151T HRP20090151T3 (en) 2004-09-29 2005-09-21 Indozolone derivatives as 11b-hsd1 inhibitors

Country Status (27)

Country Link
US (1) US7528158B2 (de)
EP (1) EP1797042B1 (de)
JP (1) JP4682207B2 (de)
KR (1) KR100856164B1 (de)
CN (1) CN101027286B (de)
AR (1) AR050952A1 (de)
AT (1) ATE420076T1 (de)
AU (1) AU2005289107B2 (de)
BR (1) BRPI0515931A (de)
CA (1) CA2581865C (de)
DE (1) DE602005012292D1 (de)
DK (1) DK1797042T3 (de)
ES (1) ES2317305T3 (de)
HR (1) HRP20090151T3 (de)
IL (1) IL182212A (de)
MX (1) MX2007003546A (de)
MY (1) MY140841A (de)
NO (1) NO20071617L (de)
NZ (1) NZ553849A (de)
PL (1) PL1797042T3 (de)
PT (1) PT1797042E (de)
RU (1) RU2392272C2 (de)
SG (1) SG148178A1 (de)
SI (1) SI1797042T1 (de)
TW (1) TWI309646B (de)
WO (1) WO2006034804A1 (de)
ZA (1) ZA200702394B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090076783A1 (en) * 2007-09-13 2009-03-19 Tyco Healthcare Retail Services Ag Digitally optimized fastener assembly and method of making the same
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2011513409A (ja) * 2008-03-06 2011-04-28 メルク・シャープ・エンド・ドーム・コーポレイション 選択的グルココルチコイドレセプターモジュレーターとしてのヘキサヒドロシクロペンチル[f]インダゾールスルホンアミドおよびこれらの誘導体
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
EP3235813A1 (de) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo-derivate
KR101796781B1 (ko) 2016-05-20 2017-11-13 한국화학연구원 신규한 인다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
WO2020144375A1 (en) 2019-01-11 2020-07-16 Grünenthal GmbH Substituted pyrrolidine amides iii
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
TWI884348B (zh) * 2021-01-06 2025-05-21 日商中外製藥股份有限公司 酸性官能基的烷基化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84944A (en) 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
BRPI0417687A (pt) * 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade

Also Published As

Publication number Publication date
NZ553849A (en) 2010-04-30
KR20070047839A (ko) 2007-05-07
EP1797042B1 (de) 2009-01-07
CA2581865C (en) 2010-04-20
JP4682207B2 (ja) 2011-05-11
KR100856164B1 (ko) 2008-09-03
ATE420076T1 (de) 2009-01-15
DK1797042T3 (da) 2009-03-02
TWI309646B (en) 2009-05-11
RU2007116033A (ru) 2008-11-10
MY140841A (en) 2010-01-29
AU2005289107A1 (en) 2006-04-06
IL182212A0 (en) 2007-07-24
CN101027286A (zh) 2007-08-29
WO2006034804A1 (en) 2006-04-06
NO20071617L (no) 2007-04-20
JP2008514659A (ja) 2008-05-08
MX2007003546A (es) 2007-05-18
RU2392272C2 (ru) 2010-06-20
CA2581865A1 (en) 2006-04-06
ES2317305T3 (es) 2009-04-16
SI1797042T1 (sl) 2009-04-30
DE602005012292D1 (de) 2009-02-26
AR050952A1 (es) 2006-12-06
US7528158B2 (en) 2009-05-05
EP1797042A1 (de) 2007-06-20
US20060069269A1 (en) 2006-03-30
BRPI0515931A (pt) 2008-08-12
PT1797042E (pt) 2009-02-12
HK1107348A1 (en) 2008-04-03
IL182212A (en) 2011-03-31
CN101027286B (zh) 2011-05-25
PL1797042T3 (pl) 2009-06-30
AU2005289107B2 (en) 2010-12-16
ZA200702394B (en) 2008-11-26
TW200626558A (en) 2006-08-01
SG148178A1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
EP1724262A4 (de) 1-(2h)-isochinolonderivat
WO2006109075A3 (en) Hydroxybenzamide derivatives and their use as inhibitors of hsp90
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
MX2009006024A (es) Derivados de heteroaril piridopirimidona sustituidos.
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
AR049739A1 (es) Derivados de aril-piridina
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
HRP20020175B1 (hr) N-heterociklički derivati kao inhibitori nos
PE20081775A1 (es) Compuestos macrociclicos como inhibidores del factor viia
ATE463483T1 (de) 6-substituierte isochinolinderivate als rock-1- inhibitoren
MXPA05008619A (es) Derivados novedosos de 2-piridincarboxamida.
NO20090952L (no) N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav
EA200201259A1 (ru) Производные бензимидазола, их получение и терапевтическое применение
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
HRP20080493T3 (hr) Supstituirani kinolinski derivati kao mitotski inhibitori kinezina
DK1585493T3 (da) Triazinderivater som UV-absorbenter
TW200745034A (en) New compounds
TW200745032A (en) Novel heterobicyclic derivatives
NO20055568L (no) Substituerte 1,4-diazepiner og anvendelser derav
EA200971060A1 (ru) Гетероариламидные пиримидоновые производные
WO2008155670A3 (en) Arylamide pyrimidone compounds
EA200971062A1 (ru) Производные ариламидпиримидона
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata